










More than 50% of patients with pros-
tate, breast or lung cancer will develop 
painful bone metastases.1 The prevalence 
of bone pain among patients with advanced 
malignancy is between 60 and 90%.2 The 
purpose of treating bone metastases is to 
relieve pain, reduce the use of steroids and 
maintain motion.1 The use of high doses of 
opioids causes severe side effects, includ-
ing nausea, vomiting, constipation and 
sedation, all of which decrease the patients’ 
quality of life.3
Radiotherapy and radionuclide therapy 
help to diminish the opioid dose.3 External 
beam irradiation is highly effective for bone 
pain relief and may occasionally result in 
reduction of tumor mass,1,4 but it should 
not be used in multifocal metastases.4,5 
Hemibody radiation therapy can be used 
in these cases, but it is associated with an 
unpredictable degree of toxicity, particularly 
when the lung and the gastrointestinal tract 
are radiated.4 
Radionuclide treatment of the pain 
caused by bone metastases is a good option. 
Radionuclides are deposited in the metastatic 
lesion at a rate of 17:1, in comparison with 
the normal bone, and therefore the radiation 
dose to the normal bone marrow outside of 
the lesion is very low.6
The objective of this study was to 
evaluate the response to treatment of bone 
pain secondary to metastases from different 





Fifty-eight patients with pain due to bone 
metastases and without effective control via 
conventional therapy were studied, after 
their informed consent had been obtained. 
Thirty-four were male and 24 were female. 
Their mean age was 62 years (19-85 years). 
Thirty-one patients had prostate cancer, 
twenty had breast cancer, three had lung 
cancer, one had lung hemangioendothelioma, 
one had parathyroid adenocarcinoma, one 
had osteosarcoma and one had an unknown 
primary tumor. 
Procedures for treatment  
with 153Sm-EDTMP
The criteria utilized for including patients 
in this treatment protocol were:
1.  Presence of pain secondary to bone me-
tastases with no relief from conventional 
drug therapy and a positive bone scan 
using 99mTc-MDP (Figure 1);
2.  White blood cell count of over 2,000/µl; 
platelet count of over 50,000/µl; hemo-
globin count of over 5.0 g/dl.
On the day of the treatment with 153Sm-
EDTMP, patients were required to quantify their 
pain on a scale from 0 to 10 (score 0 = no pain; 
score 10 = maximum pain).3 The objective crite-
ria for pain quantification that the patients were 
asked to use as guides for pain scoring were:
1.  Whether the patient was still able to 
walk;
2.  Whether the patient was waking up be-
cause of the pain;
• Elba Cristina Sá de Camargo   
   Etchebehere
• Carlos Araújo Cunha Pereira Neto
• Mariana Cunha Lopes de Lima
• Allan de Oliveira Santos
• Celso Darío Ramos
• Cleide Maria Silva
• Edwaldo Eduardo Camargo
Treatment of bone pain 
secondary to metastases using 
samarium-153-EDTMP
Division of Nuclear Medicine, Department of Radiology, and Research 
Committee, School of Medical Sciences, Universidade Estadual de 
Campinas (Unicamp), Campinas, São Paulo, Brazil
CONTEXT: More than 50% of patients with prostate, 
breast or lung cancer will develop painful bone 
metastases. The purpose of treating bone metas-
tases is to relieve pain, reduce the use of steroids 
and to maintain motion. 
OBJECTIVE: To evaluate the use of samarium-153-
EDTMP (153Sm-EDTMP) for the treatment of bone 
pain secondary to metastases that is refractory to 
clinical management.
TYPE OF STUDY: Retrospective.
SETTING: Division of Nuclear Medicine, Universidade 
Estadual de Campinas (Unicamp).
METHODS: Fifty-eight patients were studied (34 males) 
with mean age 62 years; 31 patients had prostate 
cancer, 20 had breast cancer, three had lung 
cancer, one had lung hemangioendothelioma, 
one had parathyroid adenocarcinoma, one had 
osteosarcoma and one had an unknown primary 
tumor. All patients had multiple bone metastases 
demonstrated by bone scintigraphy using 99mTc-
MDP,and were treated with 153Sm-EDTMP. Re-
sponse to treatment was graded as good (pain 
reduction of 50-100%), intermediate (25-49%) 
and poor (0-24%).
RESULTS: All patients showed good uptake of 
153Sm-EDTMP by bone metastases. Among the 
patients with prostate cancer, intermediate or 
good response to therapy occurred in 80.6% 
(25 patients) and poor response in 19.4% (6). 
Among the patients with breast cancer, 85% 
(17) showed intermediate or good response to 
therapy while 15% (3) showed poor response. 
All three patients with lung cancer showed poor 
response to treatment. The lung hemangioendo-
thelioma and unknown primary lesion patients 
showed intermediate response to treatment; the 
osteosarcoma and parathyroid adenocarcinoma 
patients showed good response to treatment. No 
significant myelotoxicity occurred. 
DISCUSSION: Pain control is important for improving 
the quality of life of patients with advanced can-
cers. The mechanism by which pain is relieved with 
the use of radionuclides is still not yet completely 
understood, however, the treatment is simple and 
provides a low risk of mielotoxicity. 
CONCLUSION: Treatment with 153Sm-EDTMP can 
control the pain secondary to bone metastases 
effectively in most patients with breast and prostate 
cancer without significant side effects.
KEY WORDS: Samarium. Pain. Metastasis. Breast 
cancer. Prostate cancer. 
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3.  Whether the patient needed help for eat-
ing, walking and personal hygiene. 
The injection protocol utilized was as 
follows. Patients received an intravenous 
injection of 37-59.2 MBq/kg (1.0-1.6 mCi/
kg) of 153Sm-EDTMP. Forty-three patients 
(74.2%) received 37 MBq/kg, one (1.7%) 
received 40.7 MBq/kg, four (6.9%) received 
44.4 MBq/kg, four (6.9%) received 48.1 
MBq/kg, one (1.7%) received 55.5 MBq/kg, 
three (5.2%) received 59.2 MBq/kg and two 
(3.4%) received 59.2 MBq/kg.
Whole body imaging in the anterior and 
posterior positions were obtained four hours 
after dose administration and the patients 
remained in the nuclear medicine laboratory 
during this period. Three nuclear medicine 
physicians read the images. 
Blood tests were performed before treat-
ment with 153Sm-EDTMP and after 3, 4 
and 6 weeks had passed. The pain score was 
monitored on a monthly basis. The response 
to treatment was considered to be good when 
the pain score decreased by 50-100%. It was 
considered to be intermediate when the pain 
score decreased by 25-49% and poor when 
the pain score decreased by 0-24%.    
Statistical analyses
The chi-squared test and Fisher exact test 
were used to verify associations or compare 
proportions. The chi-squared test was used 
for comparison of responses to therapy versus 
age and leukocyte counts versus dose. The 
Fisher exact test was used for comparison of 
response to therapy versus tumor type or dose, 
and platelet counts versus dose. 
For comparisons of continuous variables, 
the Mann-Whitney test was used for pairs of 
groups, and the Kruskal-Wallis test for three or 
more groups (response to treatment compared 
with age, dose and different types of tumor). 
When two different time intervals were 
compared in the same sample, such as the 
comparison between the initial pain score and 
the pain score after six months, in relation to 
tumor type, the Wilcoxon test was applied. 
To verify linear associations between pairs 
of continuous variables, such as the compari-
son between doses and blood counts, regard-
less of the tumor type, the Spearman linear 
correlation coefficient was used. The level of 
significance used was 5%. 
RESULTS
All 58 patients showed good uptake of 
153Sm-EDTMP by bone metastases (Figure 
2). Among them, 32 (55.2%) were good 
responders to treatment with 153Sm-EDTMP, 
13 (22.4%) were intermediate responders 
and 13 (22.4%) were poor responders. No 
significant difference was noted between 
patient outcome and tumor type, when the 
tumors were grouped as prostate, breast and 
other tumors (p = 0.0846; Fisher exact test) 
(Table 1). 
The 32 good responders remained free 
from pain for an average of 5.75 months, and 
22 patients (68.75%) remained without pain 
for at least six months. 
Sixteen of the 31 patients with prostate 
cancer were good responders, nine were 
intermediate responders and six were poor re-
sponders (Table 1). Fourteen of the 20 patients 
with breast cancer were good responders, three 
were intermediate responders and three were 
poor responders (Table 1). All three patients 
with lung cancer showed poor response to 
treatment with 153Sm-EDTMP.
The treatment response was not influ-
enced by gender (p = 0.5923; chi-squared 
test) or age (p = 0.4941; Kruskal-Wallis test). 
However, in the subgroup of older patients 
with prostate cancer, a better response to treat-
ment was noted (p = 0.0276; Kruskal-Wallis 
test). There was a significant decrease in the 
pain score after treatment, in comparison 
with the pre-treatment score, among patients 
with breast and prostate cancer (p < 0.0001; 
Wilcoxon test) (Table 1).
No significant difference was observed be-
tween the administered dose and the treatment 
response, for patients with prostate cancer (p 
= 0.8754; Fisher exact test), breast cancer (p 
= 0.7887; Fisher exact test) and other tumor 
types (p = 0.7893; Fisher exact test).
A reduction in platelet and white blood 
cell counts was noted. At a time of three to 
four weeks after treatment, twenty patients 
(34%) had platelet counts of less than 
100,000/mm3 and four patients (6.9%) had 
less than 50,000/mm3, although no bleed-
ing occurred. All count levels had returned 
to normal by six weeks after the treatment 
(Table 1). 
There was no significant correlation 
between the platelet count variation and the 
administered dose (p = 0.8824; ρ = 0.01986; 
Spearman linear correlation coefficient). 
Nor was there between the white blood cell 
count variation and the administered dose 
(p = 0.9743; ρ = 0.00432; Spearman linear 
correlation coefficient).
DISCUSSION
Approximately 60% of patients with 
metastatic cancer suffer from bone pain, 
which limits the individual’s autonomy and 
social life. Control of such pain is therefore 
important for improving patients’ quality of 
life.7 External beam radiotherapy can reach 
bone pain relief rates of 80-85%, but this 
method cannot be used to treat multiple 
Table 1. Patient outcome in a protocol of bone pain treatment, according to tumor type; dispersion values for white  
blood cells and platelet counts per mm3 at the 4th week after treatment using 153Sm-EDTMP;  
initial pain score and pain score after six months, according to tumor type
Tumor type


























































































SD = standard deviation; WBC = white blood cells. * Wilcoxon test for related samples; † Frequency of missing data = 1 (refers to patient  #58, whose primary tumor was unknown): percentages are calculated in relation to a sample 
of 57 patients; p‡ = 0.0846; Fisher exact test.
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ing the quality of life.11,12 In a study in which 
twenty patients with osteoblastic metastases 
were treated with 153Sm-EDTMP, the amount 
of analgesic therapy was reduced in 79% of 
the patients.13 
The mechanism responsible for pain relief 
has not been entirely elucidated. The reduc-
tion of the intra-medullary pressure does not 
account for the rapid pain relief that may 
occur a few days after the radionuclide ad-
ministration, since the absorbed radiation dose 
delivered has not yet destroyed a sufficient 
quantity of tumor cells.2 One possible explana-
tion would be that tumor necrosis induced by 
radiation would result in the death of cells that 
participate in the inflammatory and immuno-
logical processes, consequently reducing the 
release of bradykinins, tumor necrosis factor, 
prostaglandins and interleukins, substances 
that are known to increase pain.2,3 
The criteria used to measure the pain 
experienced by the patients in the present 
study came from the perspective of other 
clinicians with wide experience in the subject. 
“The assessment of bone pain in patients with 
cancer involves careful validation of quality, 
intensity and site of pain. It is suggested that 
some simple pain measurement be used to 
consistently rate and document the intensity 
of the patient’s pain and the degree of pain 
relief with therapeutic interventions. Several 
such scales exists, as well as an even simpler 
‘0-10’ numerical rating of pain relief. It is 
critical that the patients, not the physician 
or nurse, be allowed to measure their pain; 
numerous studies have documented how often 
second party observers underrate the intensity 
of pain and overrate the degree of pain relief 
experienced by patients.”3
The main side effect from treatment is 
myelotoxicity.14 In the present study, platelet 
counts of less than 50,000/mm3 occurred 
in a minority of patients (7%), which is 
in agreement with the current literature.1,4 
Among 107 patients with painful bone me-
tastases who were submitted to a dose-con-
trolled treatment study using 153Sm-EDT-
MP, 13% developed myelotoxicity, with 
platelet counts of less than 50,000/mm3.4 
Another trial, in which 34 patients with 
painful multifocal skeletal metastases were 
treated using single and repeated doses of 
153Sm-EDTMP, found similar results, with 
platelet counts of less than 50,000/mm3 in 
13%.10 No bleeding episodes were reported 
in these two studies.
Eary et al.9 administered different doses 
and noted that the highest tolerable dose was 
92.5 MBq/kg. Although myelotoxicity could 
Figure 1. Whole body imaging using 99mTc-MDP, from a patient with multiple bone metastases from breast cancer (skull, ribs, 
humeri, sternum, left clavicle, vertebral column, pelvis and femurs). The patient had not obtained pain relief using conventional 
drug therapy and was submitted to treatment using 153Sm-EDTMP.
lesions. Medical therapy may also not be ef-
fective in treating patients with disseminated 
bone metastases. Many of these treatments are 
limited in their efficacy or duration and have 
significant side effects that seriously limit the 
patients’ quality of life.8
Therapy using radionuclides deposits 
high doses of radiation in bone lesions, in 
comparison with the deposition in normal 
bone, with ratios ranging from 4:1 to 17:1, 
and such therapy is therefore of great use 
in the treatment of disseminated metastatic 
bone disease.1 
The kinetics and biodistribution of 153Sm-
EDTMP and 99mTc-MDP are very similar.9 
153Sm-EDTMP has high affinity for skeletal 
tissue and concentrates in areas with high bone 
metabolism. Within two to three hours after 
injection, 50% to 66% of the administered 
dose concentrates in bone, and 33% to 50% is 
excreted by the kidneys.1 Less than 2% of the 
administered dose is localized in non-osseous 
tissues, and this is mainly in the liver.1,10
The use of radionuclides for treatment 
of bone metastases has the aims of decreasing 
pain and the use of analgesics, and improv-
Sao Paulo Med J 2004;122(5):208-12.








lenot be predicted, it was easily controlled with platelet transfusion.9 Resche et al.4 observed 
pain relief in 55% of patients that received 
18.5 MBq/kg of 153Sm-EDTMP, while 70% 
of patients that received 37 MBq/kg had pain 
relief. These authors also observed a higher 
survival rate among those patients with 
breast cancer that received 37 MBq/kg. The 
dose can be repeated, if clinically indicated.4 
Menda et al.15 treated one prostate cancer 
patient more than once, obtaining good pain 
control with little reduction in platelet and 
white blood cell counts. 
In the present study, among the patients 
that received 37 MBq/kg (74%), 77% had 
pain relief, although a better response was 
not seen with doses above 37 MBq/kg. The 
administered dose had no direct effect on 
patient outcome. In 78.9% of the patients, 
there was good or intermediate treatment 
response, which is in agreement with the 
current literature.13,14,16,17 In another study, 
a single dose of 153Sm-EDTMP in the pal-
liative treatment of 72 patients with painful 
skeletal metastases provided palliation in 
83.8% of the patients.14
Among a group of 54 patients treated us-
ing 153Sm-EDTMP, excellent results were seen 
in 66%, with complete pain control.17 Turner 
et al.10 studied 28 patients with disseminated 
skeletal metastases who were submitted to 
therapy using 153Sm-EDTMP, and noted pain 
relief in 79%. The response duration ranged 
from 4 to 35 weeks, similar to the results in 
the present study. 
Systemic treatment using radionuclides is 
simple to administer, with few side effects. It 
improves patient mobility, reduces patients’ 
dependence on steroidal and non-steroidal 
analgesics and improves patients’ quality of 
life and survival.12
CONCLUSION 
Treatment with 153Sm-EDTMP can control 
the pain secondary to bone metastases18 effec-
tively in most patients with breast and prostate 
cancer without significant side effects.
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Tratamento da dor óssea secundária a metástases 
com EDTMP-153-samário
CONTEXTO: Mais de 50% dos pacientes com 
câncer de próstata, mama ou pulmão desen-
volverão dor óssea secundária a metástases. 
O tratamento da dor óssea metastática visa 
minimizar a dor, reduzir o uso de opióides e 
manter os movimentos. 
OBJETIVO: Avaliar o uso de EDTMP-153Sm 
para tratamento da dor óssea secundária 
a metástases refratária a tratamento com 
opióides. 
TIPO DE ESTUDO: Retrospectivo.
LOCAL: Divisão de Medicina Nuclear, Universi-
dade Estadual de Campinas (Unicamp).
MÉTODOS: 58 pacientes foram estudados (34 
homens), com média de idade de 62 anos. 31 
pacientes com neoplasia de próstata, 20 com 
neoplasia de mama, três pacientes com câncer 
de pulmão, um com hemangioendotelioma 
de pulmão, um com adenocarcinoma de 
paratireóide, um com osteosarcoma e um 
paciente que apresentava um tumor primário 
desconhecido. Todos apresentavam múltiplas 
metástases ósseas à cintilografia óssea com 
MDP-99mTc e foram tratados com EDTMP-
153Sm. A resposta ao tratamento foi graduada 
em boa (redução da dor em 50 - 100%), 
intermediária (25-49%) e má (0-24%).
RESULTADOS: Todos os pacientes apresenta-
vam boa captação de EDTMP-153Sm nas 
metástases ósseas. Dentre os doentes com 
câncer de próstata, resposta intermediária ou 
boa ocorreu em 80.6% (25 pacientes) e má 
resposta em 19.4% (6). Dentre os pacientes 
com câncer de mama, 85% (17) apresenta-
ram resposta intermediária ou boa à terapia 
enquanto 15% (3) apresentaram má resposta. 
Todos os três pacientes com câncer de pulmão 
apresentaram resposta pobre ao tratamento. 
Os doentes com hemangioendotelioma de 
pulmão e com o tumor primário desconhe-
cido apresentaram resposta intermediária ao 
tratamento; os pacientes com osteossarcoma 
e com o adenocarcinoma de paratireóide 
apresentaram boa resposta. Mielotoxicidade 
significativa não ocorreu. 
DISCUSSÃO: O controle da dor é importante 
para melhorar a qualidade de vida do doente 
com câncer avançado. O mecanismo de alívio 
da dor com radionuclídeos ainda não foi eluci-
dado, mas o tratamento é de simples adminis-
tração e baixo risco de mielotoxidade.
CONCLUSÃO: Tratamento com EDTMP-153Sm 
pode controlar a dor secundária a metástases 
ósseas de forma efetiva na maioria dos pacien-
tes com câncer de próstata e câncer de mama 
sem efeitos colaterais significativos. 
PALAVRAS CHAVES: Samário Dor. Metástase 
neoplástica. Neoplasias mamárias. Neoplasias 
prostáticas. 
RESUMO
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